Astria Therapeutics Azioni (NASDAQ: ATXS)

Ultime notizie per Astria Therapeutics (NASDAQ:ATXS) Azioni

ASTRIA THERAPEUTICS INC

Astria Therapeutics

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

Astria Therapeutics Inc

Apogee Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>) reported quarterly losses of $(0.95) per share which beat the analyst consensus estimate of $(1.25) by 24 percent. This is a 48.44 percent decrease over losses of $(0.64) per share from the same period last year.

Earnings

Earnings Beats

News

APGE

Apogee Therapeutics Q1 EPS $(0.95) Beats $(1.25) Estimate

<ul>
<li>Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to MASH following 96 weeks of treatment with efruxifermin (EFX)</li>
<li>Presented two oral presentations and a poster presentation highlighting the latest data and new analyses from 96-week SYMMETRY and HARMONY clinical studies at EASL Congress 2025</li>
<li>SYMMETRY study results published in New England Journal of Medicine</li>
<li>Raised $402.5 million in gross proceeds in a follow-on public offering in January 2025,&nbsp;resulting in reserves of cash, cash equivalents, and marketable securities of $1,128 million at March 31, 2025</li>
</ul>

AKRO

Akero Therapeutics Q1 2025 EPS $(0.90) Beats $(0.99) Estimate, Cash, Cash Equivalents, And Short- And Long-term Marketable Securities As Of March 31, 2025, Were $1.128B, Will Be Sufficient To Fund Its Current Operating Plan Into 2028

<a href="https://www.globenewswire.com/Tracker?data=PjCTSVgCkDiVs5e9YCoOHU0TgyVMvy1h5xWtw75s1DwD0uo9CHHJsqoASOWAmvdSJabJSfzaFt2XUqJDdR0Q7g==">Viasat, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>), a global leader in satellite communications, has confirmed the GX10A and GX10B satellite payloads are now available to deliver services for government customers, with commercial maritime and aviation services anticipated to follow throughout fiscal year 2026. Viasat successfully completed in-orbit testing of the payloads late last year and government services are now available.
Launched from Vandenberg Space Force Base in August 2024, the GX10A and GX10B payloads are housed on Space Norway's Arctic Satellite Broadband Mission spacecraft — ASBM-1 and ASBM-2. The satellites feature hosted payloads for the Norwegian Military and the U.S. Government, as well as a radiation monitoring capability for the European Commission. For Viasat, the GX10A and GX10B payloads are aimed to provide broadband satellite coverage over the Arctic region for government and commercial customers.

Government

Regulations

VSAT

Viasat's New Arctic Satellites Go Live for US Government Use, With Commercial Rollout Set for 2026

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.alnylam.com%2F&amp;esheet=54252800&amp;newsitemid=20250512731729&amp;lan=en-US&amp;anchor=Alnylam+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=c09d64a6df2c8aec7de70fcaf5351a15">Alnylam Pharmaceuticals, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>), the leading RNAi therapeutics company, today announced that the Company will present the latest data from its flagship transthyretin amyloidosis (TTR) franchise at the upcoming Heart Failure 2025 Congress, a scientific congress of the European Society of Cardiology, taking place May 17-20 in Belgrade, Serbia.
The latest analyses of the HELIOS-B Phase 3 study of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM), including further outcomes data on cardiovascular hospitalizations and urgent heart failure visits up to 42-months, will be presented as a late-breaking abstract in the "Hottest Trials and Trial Updates 1" session.
Data from the HELIOS-B study supported the recent approvals of AMVUTTRA&#xAE; (vutrisiran) for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults in the U.S. and Brazil. These data also supported the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of vutrisiran for the same indication. AMVUTTRA is an RNAi therapeutic that works upstream to deliver rapid knockdown of transthyretin, addressing the disease at its source, with four subcutaneous doses per year.
Additional updates to be presented include the design and rationale of the TRITON-CM Phase 3 study of nucresiran (ALN-TTRsc04), an investigational next-generation TTR silencer, in patients with ATTR-CM, as well as an additional analysis from the HELIOS-B study of vutrisiran in patients with ATTR-CM who experienced disease progression while being treated with tafamidis.

ALNY

Alnylam Pharma To Present Latest Data From Flagship Transthyretin Amyloidosis Franchise At Upcoming Heart Failure 2025 Congress

AEVA

Aeva Receives First Purchase Orders For More Than 1,000 Eve 1 Sensors From Automation Companies

<a href="https://www.globenewswire.com/Tracker?data=GWR2eGLoIi_p5untQNvqzi8pVzHF9jvBOmr9J9xvhpbL1C2bsvHbKy9WkzD1RwLlPd95txg4UThpe66PORAgnw==">Classiq</a> today announced raising $110 million in Series C funding, the largest ever for a quantum software company. The round was led by <a href="https://www.globenewswire.com/Tracker?data=Mgsm0Xq5pG57VLfeecZLoqIJnh61ux94L2fD5v4QNJNVbkRBXiEoWWZ-V9hWxcBE_GLVSdgg-HhwZuiR_Hsv6QQU2VCoGzrQwCyAQnc7Gvc=">Entrée Capital</a>, with participation from Norwest, NightDragon, funds managed by Hamilton Lane (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLNE#NASDAQ">HLNE</a>), Clal, Neva SGR, Phoenix, Team8, IN Venture, Wing, HSBC, Samsung Next and QBeat, as well as other new and existing investors.
This investment brings Classiq's total funding to $173 million, positioning the company to meet growing demand by significantly scaling its go-to-market, customer success and R&amp;D teams. Classiq will expand its global footprint to broaden its leading role in national quantum initiatives and as a cornerstone of the quantum ecosystem.

HLNE

Classiq Announces Raising $110M In Series C Quantum Software Funding

D. Boral Capital analyst Jason Kolbert maintains Medicus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDCX#NASDAQ">MDCX</a>) with a Buy and raises the price target from $14 to $27.

Price Target

Analyst Ratings

MDCX

D. Boral Capital Maintains Buy on Medicus Pharma, Raises Price Target to $27

WIIM

KDLY

KindlyMD shares are trading higher after the company announced a merger agreement with Nakamoto Holdings to start a Bitcoin treasury strategy.

<ul>
<li>MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025</li>
<li>MET-233i, a monthly, ultra-long acting amylin analog, is in Phase 1 trials as a monotherapy and&nbsp;co-administered with MET-097i, with five-week monotherapy data expected in Q2 2025.</li>
<li>MET-097o, an oral formulation of MET-097i, has been accelerated&nbsp;and alternate oral candidate MET-224o is on track, with four-week data&nbsp;for selected lead expected in late 2025.</li>
</ul>

MTSR

Metsera Q1 2025 EPS $(1.03) Beats $(1.04) Estimate, $588M Cash And Cash Equivalents Support Runway Into 2027

Bio-Techne Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) today announced it will showcase its latest spatial biology and cell and gene therapy workflow solutions at the American Society of Gene &amp; Cell Therapy (ASGCT) 2025 meeting taking place in New Orleans between May 13th – 17th at the New Orleans Ernest N. Morial Convention Center.
Bio-Techne will feature its cutting-edge advancements for cell and gene therapy development and manufacturing at booth 1537. Highlights include the new RNAscope&#x2122; protease-free workflow for visualization of biodistribution of AAV vectors, transgene mRNA, small RNAs (ASO, siRNA, miRNA) along with functional RNA and protein markers. Bio-Techne's booth will also showcase its solutions to improve cell therapy workflows, including the ProPak&#x2122; GMP cytokines in dose-optimized, single-use bags with weldable tubing for closed-system cell therapy manufacturing, and new AI-modified, designer proteins. The next-generation Simple Western Leo&#x2122; System will also be featured, with this state-of-the-art instrument enabling the simultaneous processing of up to 100 samples in a single 3-hour run.

TECH

Bio-Techne To Showcase Latest Spatial Biology And Cell And Gene Therapy Workflow Solutions At ASGCT 2025 Meeting

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and maintains $90 price target.

Reiteration

INSM

HC Wainwright & Co. Reiterates Buy on Insmed, Maintains $90 Price Target

Advantage Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADV#NASDAQ">ADV</a>) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.10) by 70 percent. This is a 13.33 percent decrease over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $821.79 million which beat the analyst consensus estimate of $774.38 million by 6.12 percent. This is a 6.51 percent decrease over sales of $879.03 million the same period last year.

Earnings Misses

Advantage Solutions Q1 EPS $(0.17) Misses $(0.10) Estimate, Sales $821.79M Beat $774.38M Estimate

Biotech

General

RNTX

Rein Therapeutics Initiates RENEW Phase 2 Trial Ff LTI-03 For Patients With Idiopathic Pulmonary Fibrosis

Sprott Physical Uranium Trust, On Behalf Of Sprott Physical Uranium Trust, Completes $25.55M Non-Brokered Private Placement

Sionna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SION#NASDAQ">SION</a>) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.44) by 40.91 percent.

SION

Sionna Therapeutics Q1 EPS $(0.62) Misses $(0.44) Estimate

D. Boral Capital analyst Jason Kolbert initiates coverage on NeuroSense Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRSN#NASDAQ">NRSN</a>) with a Buy rating and announces Price Target of $14.

Initiation

NRSN

D. Boral Capital Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $14

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rally to almost $106,000 may not yet be its peak, with technical models and macro flows aligning to support a near-term price target of $122,000, <a href="https://www.benzinga.com/money/bitcoin-price-prediction">according to a report</a>.
The move follows a well-defined breakout above the $84,500 level in mid-April and has been reinforced by strong spot buying and expanding institutional interest, according to a market update from May 12.
What Happened: This week's <a href="https://blog.coinshares.com/volume-233-digital-asset-fund-flows-weekly-report-f38946027bd6">data</a> from CoinShares further underpins the bullish thesis.
Digital asset investment products recorded $882 million in inflows globally last week, marking four consecutive weeks of growth and bringing year-to-date inflows to $6.7 billion. 
Bitcoin accounted for $867 million of that, continuing to dominate institutional allocations. 
Notably, <a href="https://www.benzinga.com/money/best-spot-bitcoin-etfs">U.S.-listed Bitcoin ETFs</a> have now amassed a cumulative $62.9 billion in net inflows since launching in January 2024, a record high.
Regionally, inflows were led by the United States ($840 million), followed by Germany and Australia, while Canada and Hong Kong saw small outflows. 
CoinShares attributes the increase in inflows to "a global rise in M2 money supply, stagflationary risks in the US and several US states approving Bitcoin as a strategic reserve asset."
Also Read: <a href="https://www.benzinga.com/markets/25/05/45332547/ethereum-explodes-25-higher-to-2-400-notches-largest-1-day-gain-in-4-years">Ethereum Explodes 25% Higher To $2,400, Notches Largest 1-Day Gain In 4 Years</a>
What Experts Are Saying: From a market structure perspective, Bitcoin&#8217;s rally has unfolded in $16,000 increments, with clear resistance and support levels established at $73,000, $84,500, and $95,000, all of which have been either broken or successfully retested, according to 10x Research.
After peaking at close to $106,000, analysts suggest that momentum remains intact, with technical models now pointing toward $122,000 as the next major target.
The trade thesis has been driven by long call spreads, specifically $100,000/$110,000, capitalizing on low implied volatility, which remains around 45% despite the ongoing price surge. 
"Being long on call spreads was the superior risk-adjusted trade," the report stated. 
Traders are now advised to consider rolling into higher strikes such as $110,000/$120,000.
Interestingly, the rally to $95,000 was driven not by leveraged futures but primarily by spot buying, notably from institutional players like Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) and ETF inflows, while many futures traders attempted to short the move. 
The failure of these counter-trades has added further weight to the bullish breakout.
Macroeconomic conditions have also provided a supportive backdrop. 
Fed Chair Jerome Powell recently downplayed tariff-related inflation as "potentially a one-time event," while tomorrow's CPI print is expected to hold steady at 2.4%. 
If inflation remains below 3% and U.S. economic data shows resilience, the incentive to exit positions may remain low. Political developments, particularly a pivot toward tax cuts and deregulation, are also cited as tailwinds.
Though Ethereum saw a significant price increase during the same period, its fund inflows remained limited at just $1.5 million, per CoinShares. 
Meanwhile, Sui (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">SUI</a>) attracted $11.7 million in inflows last week, surpassing Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), which saw outflows of $3.4 million. 
On a year-to-date basis, Sui has now pulled in $84 million, overtaking Solana's $76 million.
Despite a complex macro backdrop, Bitcoin&#8217;s price action remains spot-driven and momentum-led, with the combination of technical breakouts and record-setting institutional flows making the $122,000 target increasingly viable.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45326910/senate-democrats-question-binance-trump-stablecoin-ties-amid-blocked-stablecoin-legislation">Senate Democrats Question Binance-Trump Stablecoin Ties Amid Blocked Stablecoin Legislation</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$SOL

$SUI

MSTR

Bitcoin Taps $105,000: Here's When It Could Hit $122,000

MAIN

Main Street Says Recently Fully Exited Its Debt Investments And Partially Exited Equity Investment In Nebraska Vet AcquireCo, LLC, dba Heritage Vet Partners, Generating $55.5M Realized Gain

Lexeo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.78) by 26.92 percent. This is a 28.57 percent decrease over losses of $(0.77) per share from the same period last year.

LXEO

Lexeo Therapeutics Q1 EPS $(0.99) Misses $(0.78) Estimate

Macro Economic Events

Global

Economics

Bessent Says We're Negotiating To Prevent Workarounds By China Shipping To US Through Other Countries

Press Releases

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress

Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference

Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema

Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference

Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology

Comments

Astria Therapeutics

Notizie

Ultime notizie per Astria Therapeutics (NASDAQ:ATXS) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO